News releases | Absci Corp

Year

11 May / 22

Absci Reports First Quarter 2022 Financial and Operating Results

VANCOUVER, Wash., May 11, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today reported financial and operating results for the quarter ended

28 Apr / 22

Absci to Participate in the BofA Securities 2022 Healthcare Conference

VANCOUVER, Wash., April 28, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the company will be participating in the upcoming BofA

20 Apr / 22

Absci Expands Drug Discovery Capabilities with Opening of Absci AI Research Lab in New York City

Doubling down on in-silico drug discovery, Absci opens doors to new AAIR Lab located in Carnegie Hall Tower VANCOUVER, Wash. and NEW YORK, April 20, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to

22 Mar / 22

Absci Reports Full Year 2021 Financial and Operating Results

VANCOUVER, Wash., March 22, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today reported financial and operating results for the quarter and full

22 Mar / 22

Absci Develops Groundbreaking Machine Learning Models for In-Silico Antibody Design, Powered by NVIDIA

Absci to present in-silico drug discovery technology at NVIDIA GTC Breakthrough ML achievements highlight the viability of the computational lead optimization pipeline Absci collaborates with NVIDIA on research to accelerate and scale in-silico drug discovery platform VANCOUVER, Wash., March 22,

21 Mar / 22

Absci Appoints Dr. Andreas Busch to Board of Directors

Dr. Busch brings deep operational expertise in drug discovery to Absci’s Board VANCOUVER, Wash., March 21, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of

16 Mar / 22

Absci to Present at Global AI Conference NVIDIA GTC

VANCOUVER, Wash., March 16, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a drug and target discovery company harnessing deep learning, AI and synthetic biology to expand the therapeutic potential of proteins, today announced that Absci Lead AI Scientist Joshua Meier will be presenting

01 Mar / 22

Absci to Participate on Synthetic Biology Enabling Drug Discovery Panel at Cowen 42nd Annual Health Care Conference

VANCOUVER, Wash., March 01, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced that Sean McClain, CEO & Founder, will be participating on

17 Feb / 22

Absci to Participate in Upcoming Investor Conferences

VANCOUVER, Wash., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the company will be participating virtually in the following

11 Feb / 22

Absci to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

VANCOUVER, Wash., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the company will be participating virtually in the upcoming

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 12